United Kingdom Pharmaceuticals & Healthcare Q1 2020
The outlook for the UK market is polarised by factors relating to Brexit outcomes. In the softer Brexit scenarios, themaintenance of regulatory and customs alignment with the EU will preclude any major disruption to supply chains, pharmaceuticallicenses and NHS staffing. However, in harder Brexit scenarios including a ‘no-deal Brexit’, disruption at short-strait border crossingswould impact supply to the UK market. We note that a ‘no-deal’ Brexit remains a possibility although with a diminishing likelihood.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook